Abstract
Skin diseases remain a serious reason behind disability worldwide and they are ranked as the fourth most common cause of human illness affecting one-third of human population worldwide. Many conventional treatments are available for treating skin diseases but they have their own drawbacks. Currently, medicated foam serves the most effective purpose. The speedy development in the field of topical foams is because they are efficient and deliver instant absorption and have patient compliance. Various categories of drugs such as anti-inflammatory, anaesthetics, antifungal, skin emollients, antiseptics, antipruritics, etc. can be delivered in the form of medicated foams and have become very important delivery system for topically active agents in dermatology.
Keywords: Pressurized dosage form, medicated foam, topical application, fine dispersion, anaesthetics, antifungal.
Graphical Abstract
[1]
Shinde N. Nagesh H Aloorkar, et al Pharmaceutical foam delivery system-General consideration Indo-Am J Pharm Res. 2013; 1322-7.
[2]
Mirtic J, Papathanasiou F, Rakusa ZT, Matjaz MG, Roskar R, Kristl J. Development of medicated foams that combine hydrophilic and lipophilic drug for psoriasis treatment. Int J Pharm 2017; 524(1-2): 65-76.
[http://dx.doi.org/10.1016/j.ijpharm.2017.03.061]
[http://dx.doi.org/10.1016/j.ijpharm.2017.03.061]
[3]
Gennari CGM, Selmin F, Minghetti P, Cilurzo F. Medicated foams and film forming dosage forms as tools to improve the thermodynamic activity of drugs to be administered through the skin. Curr Drug Deliv 2019; 16(5): 461-71.
[4]
Bhowmik D, Gopinath H, Kumar PB, Duraivel S, Kumar KPS. Recent Advances in novel topical drug delivery system. Pharma Innovation 2012; 1(9): 12-31.
[5]
Chaudhari YS. Nanoparticles - A paradigm for topical drug delivery. Chron Young Sci 2012; 3: 82-5.
[http://dx.doi.org/10.4103/2229-5186.94311]
[http://dx.doi.org/10.4103/2229-5186.94311]
[6]
Zhao Y. Brown, Marc B, Jones S. Pharmaceutical foams: are they the answer to the dilemma of topical nanoparticles? Nanomed Nanotechnol Biol Med 2010; 6(2): 227-36.
[7]
Arzhavitina A, Steckel H. Foams for pharmaceutical and cosmetic application. Int J Pharm 2010; 394(1-2): 1-17.
[http://dx.doi.org/10.1016/j.ijpharm.2010.04.028]
[http://dx.doi.org/10.1016/j.ijpharm.2010.04.028]
[8]
Gorelick J, Cantrell W, Kucera K, Veverka KA, Gooding K. Patient-reported satisfaction with the fixed combination calcipotriene/betamethasone dipropionate foam for plaque psoriasis. J Drugs Dermatol 2018; 17(8): 880-4.
[PMID: 30124727]
[PMID: 30124727]
[9]
Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26(3): 61-7.
[http://dx.doi.org/10.1111/j.1468-3083.2012.04525.x]
[http://dx.doi.org/10.1111/j.1468-3083.2012.04525.x]
[10]
Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol 2007; 6(10): 1001-8.
[11]
Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72(5): 407-11.
[PMID: 14655784]
[PMID: 14655784]
[12]
Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007; 2007(3)CD000320
[13]
Jamison DT, Breman JG, Measham AR, et al. Disease control priorities in developing countries Washington (DC): The International Bank for Reconstruction and Development/The World Bank. New York: Oxford University Press 2006.
[14]
Elewski BE, Vlahovic TC. Econazole nitrate foam 1% for the treatment of tinea pedis: results from two double-blind, vehicle-controlled, phase 3 clinical trials. J Drugs Dermatol 2014; 13(7): 803-8.
[PMID: 25007362]
[PMID: 25007362]
[15]
Mei L, Chen J, Yu S, et al. Expansible thermal gelling foam aerosol for vaginal drug delivery. Drug Deliv 2017; 24(1): 1325-37.
[http://dx.doi.org/10.1080/10717544.2017.1375575] [PMID: 28920714]
[http://dx.doi.org/10.1080/10717544.2017.1375575] [PMID: 28920714]
[16]
Vedha Hari BN, Narayanan N, Dhevedaran K. Efavirenz-eudragit E-100 nanoparticle-loaded aerosol foam for sustained release: in-vitro and ex-vivo evaluation. Chem Pap 2015; 69: 358-67.
[http://dx.doi.org/10.1515/chempap-2015-0005]
[http://dx.doi.org/10.1515/chempap-2015-0005]
[17]
Martinez-Jacobo L, Villarreal-Villarreal CD. Ortiz-LA3pez R, Ocampo-Candiani J, Rojas-MartA-nez A. Genetic and molecular aspects of androgenetic alopecia. Indian J Dermatol Venereol Leprol 2018; 84(3): 263-8.
[PMID: 29595184]
[PMID: 29595184]
[18]
Purnak T, Senel E, Sahin C. Liquid formulation of minoxidil versus its foam formulation. Indian J Dermatol 2011; 56(4): 462.
[http://dx.doi.org/10.4103/0019-5154.84714] [PMID: 21965875]
[http://dx.doi.org/10.4103/0019-5154.84714] [PMID: 21965875]
[19]
Shatalebi MA, Rafiei Y. Preparation and evaluation of minoxidil foamable emu oil emulsion. Res Pharm Sci 2014; 9(2): 123-33.
[PMID: 25657781]
[PMID: 25657781]
[20]
Steven D. Shapiro Michael T. Borenstein. Method for treatment of hair loss with a combination of natural ingredients US8985124B2,.
[21]
Langevin D. Aqueous foams and foam films stabilised by surfactants. Gravity-free studies. Comptes Rendus Mécanique 2017; 345(1): 47-55.
[22]
Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. In: Lea & Febiger 1986.
[23]
Kealy T, Abram A, Hunt B, Buchta R. The rheological properties of Pharmaceutical foam: Implications for use. Int J Pharm 2008; 355(1-2): 67-80.
[PMID: 18221846]
[PMID: 18221846]
[24]
Dayan N. Foam: a unique delivery vehicle for topically applied formulations.In: formulating topical applications-a practical guide.
2016; pp. 233-60..
[26]
Huang X, Tanojo H, Lenn J, Deng CH, Krochmal L. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005; 53(1)(Suppl. 1): S26-38.
[http://dx.doi.org/10.1016/j.jaad.2005.04.028] [PMID: 15968261]
[http://dx.doi.org/10.1016/j.jaad.2005.04.028] [PMID: 15968261]
[27]
Cilurzo F, Alberti E, Minghetti P, Gennari CGM, Casiraghi A, Montanari L. Effect of drug chirality on the skin permeability of ibuprofen . Int J Pharm 2010; 386(1-2): 71-6. https://www.psoriasis.org/advance/topical-foam-improves-itch-clears-skin
[http://dx.doi.org/10.1016/j.ijpharm.2009.10.053] [PMID: 19900522]
[http://dx.doi.org/10.1016/j.ijpharm.2009.10.053] [PMID: 19900522]
Article Metrics
17
1